Omeros (OMER) Set to Announce Earnings on Monday

Omeros (NASDAQ:OMER) will post its quarterly earnings results after the market closes on Monday, April 1st.

Omeros Trading Down 1.2 %

NASDAQ OMER opened at $3.42 on Thursday. The firm has a market capitalization of $215.02 million, a PE ratio of 10.69 and a beta of 1.38. The company has a 50-day simple moving average of $3.90 and a 200-day simple moving average of $2.97. Omeros has a one year low of $0.92 and a one year high of $7.80. The company has a debt-to-equity ratio of 10.80, a quick ratio of 2.39 and a current ratio of 2.39.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday.

Institutional Trading of Omeros

Several hedge funds have recently bought and sold shares of OMER. Vanguard Group Inc. raised its position in shares of Omeros by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 3,168,936 shares of the biopharmaceutical company’s stock worth $10,362,000 after buying an additional 26,085 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Omeros during the 4th quarter worth about $95,000. Barclays PLC raised its position in shares of Omeros by 159.6% during the 4th quarter. Barclays PLC now owns 118,467 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 72,838 shares in the last quarter. Bridgeway Capital Management LLC raised its position in shares of Omeros by 70.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 186,300 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 77,100 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Omeros by 2.4% during the 4th quarter. Northern Trust Corp now owns 559,052 shares of the biopharmaceutical company’s stock worth $1,828,000 after buying an additional 13,009 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.